Physician profile
Mark T Brune
NPI 1093723140
$5,258.58
in general payments reported to CMS, 2019-2025
48 companies · $728 in 2025
The $728 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $565 · 2021: $980 · 2022: $486 · 2023: $688 · 2024: $1,106 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.28 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,072.86 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $486.63 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $424.48 | 2019-2025 | |
| Novo Nordisk INC | $329.55 | 2020-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $324.06 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $259.98 | 2019-2025 | Takhzyro |
| Abbott Laboratories | $209.20 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3, Eterna |
| Allergan, INC. | $163.12 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.23 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $139.45 | 2021-2024 | Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $122.18 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Organogenesis INC. | $120.99 | 2019-2022 | |
| Astellas Pharma US INC | $112.80 | 2019-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108.61 | 2024-2025 | Caplyta |
| Tactile Systems Technology INC | $91.10 | 2019-2024 | Entre Plus, Flexitouch Plus |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.